Le Lézard
Classified in: Health, Science and technology
Subject: Conference

Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference


Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that David Socks, President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 at 10:40 a.m. GMT at the Waldorf Hilton, London.

To access the live webcast and subsequent archived recordings for this presentation, which will be available for 30 days, please visit the Phathom Pharmaceuticals website at www.phathompharma.com.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company's website at www.phathompharma.com.


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: